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Abstract
Introduction Failure to detect co-expression of estrogen
receptor-alpha (ERα) and proliferation 'markers' such as Ki67 in
human mammary epithelium led to the view that estrogen acts
indirectly to stimulate mammary epithelial proliferation. The
mitotic index was so low in prior studies, however, that transient
co-expression of ERα and Ki67 during the cell cycle could have
been below detection limits.
Methods Immunohistochemistry was used on mammary tissue
sections from estrogen treated rhesus monkeys to investigate
co-expression of ERα and the proliferation antigen Ki67. Using
the same methods, we investigated the cell localization of
proteins involved in estrogen-induced proliferation, including
cyclin D1, stromal cell-derived factor (SDF)-1, and MYC.
Results ERα was co-expressed with the proliferation marker
Ki67 as well as with SDF-1, MYC and cyclin D1 in mammary
epithelial cells from estrogen-treated monkeys.
Conclusion ERα is expressed in proliferating mammary
epithelial cells together with the estrogen-induced proteins
MYC, cyclin D1 and SDF-1, consistent with a direct mitogenic
action by estrogen in primate mammary epithelium.
Introduction
Estrogen receptors (ERα and ERβ) belong to the nuclear
receptor family and function as hormone inducible transcrip-
tion factors in target cells [1]. ERα is thought to mediate the
mitogenic actions of estrogen by inducing the expression of
genes involved in cell proliferation, including cyclin D1, MYC
and stromal cell-derived factor (SDF)-1 [2,3]. Failure to detect
co-expression of ERα and Ki67 (a proliferation marker) in nor-
mal human mammary epithelium led to the proposal that estra-
diol acts indirectly in this tissue by stimulating ER-positive
epithelial cells to release (unknown) mitogens that then trigger
proliferation in neighboring ER-negative epithelium [4,5]. Of
note, the mammary epithelial proliferation index in these stud-
ies was very low, generally less than 5% and often closer to
1%.
Estrogen stimulates breast cancer cells in G0 to enter G1 and
progress to S phase [6], and thus one might expect to find
ERα expression in some G0 cells and through some part of
G1 phase in proliferating cells. As with most cell cycle regula-
tory proteins, Ki67 expression is tightly regulated, appearing in
mid G1 with a half-life of 60 to 90 minutes [7]. Thus, it appears
likely that during the normal mitotic cycle, ERα and Ki67 may
be co-expressed for a limited period beginning in G1. The
number of cells in G1 and the short duration of co-expression
result in a low probability of detecting the transient co-expres-
sion.
To improve our understanding of ERα action in primate mam-
mary epithelium, in the current study we have investigated the
co-expression of ERα, the proliferation marker Ki67 and estro-
gen target proteins MYC, cyclin D1 and SDF-1 in the highly
proliferative mammary epithelium from estrogen-treated rhe-
sus monkeys.
Materials and methods
We have previously shown that ovariectomy followed by short
term estrogen treatment greatly increases the mammary
epithelial proliferation index in the rhesus monkey [8]. We thus
investigated ERα and Ki67 expression using immunohisto-Page 1 of 4
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mammary epithelium in estrogen-treated monkeys. Details of
the treatment and immunohistochemical protocols have been
published [8].
For double immunofluorescence of ERα, MYC and SDF-1, fro-
zen sections (5 µm) of monkey mammary gland biopsies were
fixed in cold methanol for 4 minutes, washed twice in PBS and
then incubated with 8% bovine serum albumin for 1 h at room
temperature. The following antisera were used: ERα and Ki-67
mouse monoclonal (Novocastra Laboratories Ltd, Newcastle
upon Tyne UK), SDF-1-α rabbit polyclonal (Leinco Technolo-
gies Inc., St. Louis, MO, USA) and C-MYC mouse monoclonal
(NeoMarkers, Fremont, CA, USA). The dilution 1:50 was used
for primary antibodies. Secondary antibodies, anti-rabbit Ig-
FITC and anti-mouse Ig-Cy3 were from Sigma (Sigma-Aldrich,
St. Louis, MO USA) and Caltag Laboratories (Burlingame, CA
USA), respectively. The slides were stained with 4',6-diamid-
ino-2-phenylindole (DAPI) and examined using a Leica epifluo-
rescence microscope; fluorescence images were
automatically captured on a Photometrics cooled-CCD cam-
era (Photometrics Ltd, Tuscon, AZ, USA), using IP Lab Image
software (Scanalytics Inc., Fairfax, VA, USA).
For double immunofluorescence of ERα and cyclin D1, the tis-
sues were fixed in 8% buffered paraformaldehyde for 10 min-
utes at room temperature. Following rinses in PBS, the slides
went through heat induced antigen retrieval. The non-specific
sites were blocked with 1 × Power-block (Zymed, South San
Francisco, California, USA) and then incubated in the ERα
antibody (Novocastra F611) at a 1:200 dilution overnight at
4°C. Biotinylated anti-mouse (1:200) and ABC (1:500) anti-
bodies followed, each for 1 h at room temperature. Fluores-
cein isothiocyanate (FITC) conjugated tyramide plus was then
added for detection (1:750; Invitrogen, Carlsbad, California,
USA). Next, the sections were microwaved to eliminate endog-
enous HRP activity and the second primary antibody (rabbit
polyclonal anti-cyclinD1; Santa-Cruz sc-8396 (Santa Cruz
Biotechnology, Inc. Heidelberg, Germany)) was used at a
1:500 dilution at 4°C overnight. The staining was then devel-
oped using ABC and biotinylated tyramide (1:5000) for 5 min-
utes at room temperature and streptavidin-594 (1:2000;
Molecular Probes, Invitrogen, Carlsbad, California, USA) for 1
h at room temperature. The slides were mounted with 0.1 M
Tris and viewed in a Leica DMR fluorescent microscope. The
negative control omitting the primary antibody resulted in
nostaining.
To determine the percentage of double-labeled mammary epi-
thelial cells, an observer scored 500 to 1,000 cells for each
combination of antibodies.
Results
To evaluate co-expression of ERα and the proliferation spe-
cific marker Ki67 we used immunohistochemical detection on
thin (3 µm) serial sections through the mammary epithelium
from estrogen-treated monkeys. We found that 23 ± 10%
(mean ± standard deviation for the 4 estrogen treated animals;
approximately 1,000 cells scored for each) of mammary epi-
thelial cells were ER+/Ki67+ while 22 ± 2% were ER-/Ki67+
(Figure 1). Approximately 15% of cells were ERα+/Ki67-, and
the remaining 40% was negative for both antigens.
To investigate the co-expression of the estrogen target mole-
cules SDF-1, MYC and cyclin D1 in ERα positive cells, we
used double immunofluorescence. Co-expression of ERα and
Figure 1
Co-localization of estrogen receptor (ER)α and Ki67 in primate mam-mary epithelial cells
mary epithelial cells. (a) ERα and (b) Ki67 immunostaining (brown) are 
detected in the same epithelial cells on serial sections (3 µm) of primate 
mammary tissue, for example, cells 4–7. Bar = 20 µm.Page 2 of 4
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cells were stained positive for ERα alone and for SDF-1 alone,
respectively (Figure 2, Table 1). The remaining 46.7% of cells
was negative for both antigens. Approximately 26% of mam-
mary epithelial cells stained positive for both ERα and MYC
antibodies. No expression was observed in 48.6% of cells
while 7.2% were ERα+/MYC- and 18% ERα-/MYC+. Most
SDF-1 positive cells were also MYC positive, and vice versa
(Figure 2c, d). All our data were consistent in four different
estrogen treated animals. Finally, cyclin D1 was detected in
over 90% of ERα positive cells (Figure 3).
Discussion
This study has shown that ERα is co-expressed with the pro-
liferation antigen Ki67 in a population of normal primate mam-
mary epithelial cells under the conditions of short-term
estrogen stimulation and high rates of proliferation. In addition,
ERα is co-expressed with the estrogen-induced target pro-
teins SDF-1, MYC and cyclin D1, which are all implicated in
mammary epithelial cell proliferation. These observations indi-
cate that it is likely that estrogen has direct mitogenic effects
upon ERα-positive mammary epithelial cells and obviate the
need to invoke unknown paracrine mediators of estrogen
action in the mammary gland. Previous studies investigating
ERα and Ki67 co-expression reported very low proliferation
rates [4]. With only 1% to 2% of cells engaged in mitosis, if
ERα and Ki67 co-expression occurs for 10% to 20% of the
cell cycle, then even with 100% efficient histochemical meth-
odology, only approximately 0.2% of cells would be both ERα
and Ki67 positive, which is in the range of what has been
reported. The high rate of mammary epithelial proliferation
induced by estrogen treatment [8] in the present study pro-
vided a more optimal window of opportunity to detect transient
co-expression of ERα and Ki67. The present results are cer-
tainly more compatible with estrogen's well-established ability
to promote proliferation in ER-positive breast cancer cell lines
[5].
MYC serves as a central component of estrogen regulation of
cell cycle progression and oncogenesis [2]. ERα and MYC are
frequently over-expressed during breast cancer progression
[9]. We have previously shown that MYC expression is posi-
tively correlated with ERα expression in normal primate mam-
mary epithelium [10]. In this study, using mammary tissue
sections from the same animals, we show that more than one
fourth of the cells co-express ERα and MYC, providing in vivo
confirmation that MYC is implicated as a mediator of estro-
genic induced proliferation. A novel and important finding of
this study is that almost all the cells that express MYC also
express SDF-1. SDF-1 has recently been implicated as a
mediator of estrogen's proliferative actions in ovarian and
breast cancer cells [3]. The present finding of co-localization
of ERα and SDF-1 and MYC and SDF-1 provides the first con-
firmation that these interactions appear relevant in normal pro-
liferating mammary tissue.
Figure 2
Co-expression of Erα and its molecular targets in mammary epithelium. 
(a) Erα is detected as a red nuclear stain and SDF-1 as a yellow cyto-
plasmic stain. (b) The red duclear stain for Erα is surrounded by yellow 
cytoplasmic signal from MYC immunostaining. Arrowheads in a and b 
point to cells where the Colocalization is clear. (c and d) serial sections 
show MYC (red) and SDF-1 (green) immunostaining in the same cells. 
Bar = 20 microns.Page 3 of 4
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ERα is expressed in proliferating mammary epithelial cells
together with the estrogen-induced proteins MYC, cyclin D1
and SDF-1, consistent with a direct mitogenic action by estro-
gen in mammary epithelium.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CD and JZ contributed to the conception and design of the
study, performed immunohistochemistry experiments, statis-
tics and interpretation of data. JW, JXW and DW performed
immunohistochemistry experiments. EM, LM and JZ performed
double immunofluorescence studies. CB contributed to the
conception and design of the study and interpretation of data.
All the authors read and approved the final manuscript.
Acknowledgements
We thank Sharon Key for expert help with double immunofluorescence 
histochemistry.
References
1. Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of
estradiol and estrogen receptor signaling.  J Biol Chem 2001,
276:36869-36872.
2. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL: Downstream
targets of growth factor and oestrogen signalling and endo-
crine resistance: the potential roles of c-Myc, cyclin D1 and
cyclin E.  Endocr Relat Cancer 2005, 12(Suppl 1):S47-59.
3. Hall JM, Korach KS: Stromal cell-derived factor 1, a novel target
of estrogen receptor action, mediates the mitogenic effects of
estradiol in ovarian and breast cancer cells.  Mol Endocrinol
2003, 17:792-803.
4. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation
between steroid receptor expression and cell proliferation in
the human breast.  Cancer Res 1997, 57:4987-4991.
5. Russo J, Ao X, Grill C, Russo IH: Pattern of distribution of cells
positive for estrogen receptor alpha and progesterone recep-
tor in relation to proliferating cells in the mammary gland.
Breast Cancer Res Treat 1999, 53:217-227.
6. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J: Multi-
faceted regulation of cell cycle progression by estrogen: reg-
ulation of Cdk inhibitors and Cdc25A independent of cyclin
D1-Cdk4 function.  Mol Cell Biol 2001, 21:794-810.
7. Brown DC, Gatter KC: Ki67 protein: the immaculate deception?
Histopathology 2002, 40:2-11.
8. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA: Tes-
tosterone inhibits estrogen-induced mammary epithelial pro-
liferation and suppresses estrogen receptor expression.
FASEB J 2000, 14:1725-1730.
9. Zelinski DP, Zantek ND, Walker-Daniels J, Peters MA, Taparowsky
EJ, Kinch MS: Estrogen and Myc negatively regulate expres-
sion of the EphA2 tyrosine kinase.  J Cell Biochem 2002,
85:714-720.
10. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C,
Powell D, Bondy C: A physiologic role for testosterone in limit-
ing estrogenic stimulation of the breast.  Menopause 2003,
10:292-298.
Table 1
Co-expression of estrogen receptor-α with MYC and stromal cell-derived factor-1 in mammary epithelial cells
Double stain ERα (+) % MYC (+) % SDF (+) % Both (+) % None %
ERα/MYC 7.2 18 26.2 48.6
ERα/SDF 9 19.3 25 46.7
One thousand cells were counted for each combination of antibodies in mammary gland sections of four estrogen treated monkeys stained for 
estrogen receptor (ER)α/MYC and ERα/stromal cell-derived factor (SDF)-1 using double immunofluorescence.
Figure 3
Colocalization of estrogen receptor (ER)α and cyclin D1 in mammary epithelial cells  li   in a ary epithelial cel s. Double immunofluorescence in the same tissue section shows: 
(a) ERα, green nuclear staining; (b) cyclinD1, red nuclear staining; (c) ERα and cyclinD1: yellow nuclear staining. Arrows indicate cells co-express-
ing ERα and cyclinD1. Bar = 20 µm.Page 4 of 4
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